Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0038454 (
stroke
)
147,016
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Recurrent retinal branch artery occlusions, carotid thromboembolism, cerebral venous thrombosis, transient brainstem ischemia, and massive brainstem and cerebral infarction complicated the course of
inflammatory bowel disease
in 5 patients. Three patients had ulcerative colitis and 2 had regional enteritis. The usual risk factors for
stroke
were absent. Neuropathological examination in 1 patient showed in situ thrombosis of small cerebral and brainstem arteries and veins. Coagulation studies showed thrombocytosis, short partial thromboplastin times, and elevation of fibrinogen and Factor VIII levels. Platelet counts and coagulation factors returned toward normal after control of intestinal inflammation in each of the 4 surviving patients.
Inflammatory bowel disease
can be accompanied by a hypercoagulable state that predisposes to
stroke
.
...
PMID:Cerebral and retinal vascular complications of inflammatory bowel disease. 44 68
One adolescent and two young adults had ulcerative colitis and cerebral thrombosis. All survived with neurologic deficit. These patients had no other predisposing factor for cerebrovascular disease. Systemic arterial and venous thromboembolic complications occur often in ulcerative colitis, but
stroke
is uncommon. Abnormalities in the early stages of clotting may be responsible, and the risk of thromboembolic phenomena in young patients seems to increase with exacerbations of this form of chronic
inflammatory bowel disease
, and possibly with regional enteritis as well.
...
PMID:Strokes and ulcerative colitis. 56 88
There is an increased incidence of central nervous system thromboembolic events in young patients with
inflammatory bowel disease
. A 33-yr-old woman previously diagnosed with pseudotumor cerebri suffered superior sagittal and transverse sinus thromboses during a severe flare of ulcerative colitis. These were documented on contrast computed tomographic (CT) and magnetic resonance imaging (MRI) scans.
Stroke
may be more common in patients with ulcerative colitis than in patients with Crohn's disease; arterial disease is more prevalent than venous and dural sinus disease, and is correlated with an active phase of
inflammatory bowel disease
. It is difficult to assess whether there is a relationship to concurrent steroid use, and a consistent relationship to duration of
inflammatory bowel disease
or to other extraintestinal manifestations is not apparent.
...
PMID:Cerebrovascular complications of inflammatory bowel disease. 199 21
The frequency of known causative factors of cerebral infarction was studied in 244 cases of first ever
stroke
due to cerebral infarction proved by computed tomography or at necropsy who were registered in the first two years of a prospective community based study. Risk factors for cerebral infarction were present in 196 (80%) cases; hypertension in 126 (52%); ischaemic heart disease in 92 (38%); peripheral vascular disease in 60 (25%); a cardiac lesion that was a major potential source of embolism to the brain in 50 (20%); transient ischaemic attacks in 35 (14%); cervical arterial bruit in 33 (14%); and diabetes mellitus in 24 (10%). Thirty one patients (13%) were in atrial fibrillation. Of the 48 patients who were free of risk factors or a major potential cardiac source of embolism at the time of the
stroke
, 18 were found to have hypertension after the
stroke
and 10 to have non-atheromatous non-embolic conditions (migrainous cerebral infarction (three), arteritis (two),
inflammatory bowel disease
(one), arterial trauma (one), autoimmune disease (one), carcinoma of the thyroid (one), and major operation (one). In 20 patients no causative factors could be identified. In this unselected series of patients with first ever
stroke
due to cerebral infarction most of the strokes were presumed to be due to either atheromatous arterial disease or embolism from the heart, and only 4% (95% confidence interval 2 to 7%) were probably due to non-atheromatous non-embolic causes. This has implications for research into strokes and allocation of public health expenditure.
...
PMID:Predisposing factors for cerebral infarction: the Oxfordshire community stroke project. 249 1
The incidence of transient (less than 24 hour) neurologic loss was evaluated from a survey returned by 80/87 members of Cornell's Department of Neurology. Transient CNS dysfunction was reported by 25/80 (32%; 95% confidence interval, 21 to 44%). In most (15) only vision was affected, but ten (13%; 6 to 23%) reported nonvisual deficits. In nine of these ten, loss of power, balance, or coordination was noted, sometimes with other symptoms (visual in two), and the tenth subject had speech arrest. Seven of the ten had more than one episode. Episodes in these ten individuals began at age less than 30 in four, 30 to 34 in five, 35 to 39 in none, and 40 to 44 in one. The reported frequency of migraine was nonsignificantly higher in patients with nonvisual (4/10, 40%) or visual (7/15, 47%) episodes than in respondents without episodes (12/55, 22%; chi 2(2) = 4.3). Except for
inflammatory bowel disease
in one respondent, no obvious cause of the nonvisual episodes was evident from follow-up structured interviews. Five of the ten with nonvisual loss and eight of the 15 with isolated visual symptoms thus had no obvious cause for their episodes. Follow-up is limited to a median of 5 years, but none of the 25 has had any residual deficit or chronic neurologic disorder, suggesting that these relatively common episodes of CNS deficit are benign. As new, hyperacute
stroke
therapies emerge, efforts to distinguish these episodes from true, early strokes will become increasingly important.
...
PMID:Transient CNS deficits: a common, benign syndrome in young adults. 336 63
The evidence of the effects of combined oral contraceptives (COCs) on mortality and morbidity is reviewed. All the 11 case-control studies published since 1980 reported and approximate halving of endometrial cancer risk among COC users. The CASH study showed that the protective effect was apparent after 12 months' use, and users had 40% of the risk of non-users after 2 years' use. A study showed that 5 patterns of self-perceived prolonged, heavy, frequent, irregular, or painful bleeding during menstruation were reported less frequently in COC users than in users of other methods. Benign breast disease is rarer, and functional ovarian cysts are less frequent in COC users. Lower-dose preparations may carry a lower risk of myocardial infarction. Smoking possibly potentiates the risk associated with oral contraceptive (OC) use, and it is a major risk factor for myocardial infarction. The Oxford/FPA study found a 2-3-fold increase in incidence of non-haemorrhagic
stroke
among current OC users. The epidemiologic data on the current risk of venous thromboembolism in relation to OC use are equivocal. New lower dose COCs have a smaller adverse effect on the lipid profile: they cause a smaller increase in low density lipoprotein cholesterol (LDL) and a variable but smaller decrease in high density lipoprotein cholesterol (HDL). The large CASH study, based on 2088 cases, found a significantly elevated relative risk (2.7) of breast cancer, but only in women who had used the OC for at least 11 years. Of 6 case-control studies of hepatocellular carcinoma and OC use published since 1983, all but one showed a large elevated relative risk of around 4-fold. Delayed return of fertility has been observed in nulliparous women 30 who had 2 years; continuous exposure to COCs, although this may not be associated with low-dose, modern OCs. Malignant melanoma, pituitary adenoma, gallbladder disease, and chronic
inflammatory bowel disease
have been possibly associated with adverse side effects, but results are so far inconclusive.
...
PMID:Combined oral contraceptives: risks and benefits. 832 3
The 21-aminosteroid tirilazad mesylate (U74006F) is a lipophilic antioxidant and free radical scavenger that has been reported to attenuate brain or spinal cord injury caused by trauma,
stroke
, ischemia and reperfusion injury. In this study, we have examined the effect of U74006F in reducing the inflammatory parameters of trinitrobenzene sulfonic acid (TNBS)-induced
inflammatory bowel disease
(
IBD
) in rats. To induce
IBD
, rats were given ethanolic TNBS intracolonically. Rats received either 1) TNBS and U74006F 2) TNBS and vehicle or 3) saline and vehicle. Rats were sacrificed 1, 2 and 3 weeks after
IBD
induction. Colon to body weight ratio (an index of tissue edema) was markedly increased in the vehicle-treated
IBD
rats after 1 week of administration of TNBS. The ratio was significantly lower after U74006F treatment and the trend remained even after 3 weeks of chronic inflammation. Myeloperoxidase (MPO) activity in vehicle-treated
IBD
rats was substantially increased compared with controls during the entire 3 weeks of the experiment. U74006F-treated animals had significantly reduced MPO activity (60% lower) when compared with vehicle-treated animals at the end of the second and third weeks. These observations were confirmed by histopathology studies showing reduced granulocyte infiltration after drug treatment. U74006F treatment decreased basal (by 70%) and fMLP stimulated (by 75%) superoxide generation from colonic tissue from
IBD
rats compared with vehicle treatment after 2 weeks, but there was no apparent difference in superoxide generation among all three groups after 3 weeks. The results of this study suggested that administration of U74006F effectively reduces the inflammatory parameters in this chronic rat model of
IBD
. As such, U74006F may be therapeutically beneficial for the treatment of
IBD
in humans.
...
PMID:The 21-aminosteroid tirilazad mesylate can ameliorate inflammatory bowel disease in rats. 855 41
Cerebrovascular accidents are rare but well documented in patients with Crohn's disease. Up to 10% of hypercoagulable state manifestations reported in association with
inflammatory bowel disease
are ischemic strokes. However, no clear mediating factor has thus far been suggested. A 44-year-old woman with Crohn's disease for 25 years developed a left temporal
stroke
associated with anticardiolipin antibody and lupus anticoagulant suggesting antiphospholipid syndrome. A thorough evaluation did not reveal any other risk factor for ischemic
stroke
. No possible sources of emboli were found in the carotids and heart, and no deficiencies of protein C and activated protein C, protein S, and anti-thrombin III leading to hypercoagulable state were present. There may be a possible association between antiphospholipid syndrome and hypercoagulable state in Crohn's disease.
...
PMID:Antiphospholipid syndrome manifested by ischemic stroke in a patient with Crohn's disease. 874 56
If one reviews the literature with zeal, it is increasingly apparent that few organs escape recruitment when
IBD
is chronic or progressive. Insights into mucosal pathophysiology have helped with understanding the more frequent extraintestinal manifestations, but the mechanisms attendant to the development of less common events (e.g. acute pancreatitis, concurrent gluten sensitive enteropathy, or active pulmonary disease) remain either poorly studied or obscure. It is particularly interesting, however, to read reports of abnormal pulmonary function, generally of the obstructive type, correlated to measurements of abnormal intestinal permeability in patients with either active pulmonary sarcoid or pulmonary involvement in Crohn's disease. It has been further speculated that similarities in the mucosal immune system of the lung and intestine are responsible for evidence of bronchial hyperreactivity in patients with active
IBD
. Finally, it is important to recognize that extensions of the inflammatory process are not restricted to the development of organ-based events but may be responsible for some of the most frequent systemic abnormalities detected in
IBD
patients. It is now also well confirmed that the cytokine environment in
IBD
can support activated coagulation and, in some clinical situations, overt vascular thrombosis. The cerebrovascular complications of
IBD
are well recognized and range from peripheral venous thrombosis to central
stroke
syndromes and pseudotumor cerebri. Reports of focal white matter lesions in the brains of patients with
IBD
or an increased incidence of polyneuropathy may be other clinical examples of regional microvascular clotting. Microvascular injury appears to be more ubiquitously present, with reports ranging from a speculated primary causative role (e.g., granulomatous vasculitis in the mesenteric circulation) to the utility of nailbed vasospasm, in Crohn's disease, as a clinical marker for disease activity. It is also reported that IL-6 suppression of erythropoietin production is a major feature of the chronic anemia seen in active
IBD
. Moreover, the capacity of peripheral monocytes from active
IBD
patients to secrete TNF and IL-8 is reported predictive for the degree of therapeutic response from recombinant erythropoietin. These collected observations constitute another excellent example of the symmetry between basic science and clinical utility. It is from the context of applied basic science that many future therapies will arise. Empiricism will lose much of its appeal as clinical observations will be increasingly translated into cellular language. Already in animal models, elemental diets diminish IL-6-related acute inflammatory injury, and reductions in dietary lipid alter the antigenicity of bacteria. Provocatively, in humans, unconfirmed reports have even associated diet therapy with the resolution of uveitis and pyoderma gangrenosum. It is likely that efforts will also be made to induce oral tolerance if specific triggering proteins are discovered or to alter bowel flora if such an arcane area of investigation becomes resurgent.
...
PMID:Extraintestinal considerations in inflammatory bowel disease. 880 40
A 40 year old woman presented successively an arterial and a venous cerebral thrombosis, revealing an
inflammatory bowel disease
. Digestive manifestations were very poor until then.
Stroke
is a rare complication of
inflammatory bowel disease
, and is usually correlated with and active phase of the disease. The mechanism by which the thrombogenic process occurs is unclear. The possible prothrombotic role of hemostasis disorders and the role of an angiitic process are discussed.
...
PMID:[Cerebral thrombotic complications, arterial and venous, disclosing inflammatory bowel disease]. 903 46
1
2
3
4
5
6
7
8
Next >>